Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.8K

MicroRNA-206 serves as a tumor suppressor in pediatric acute myeloid leukemia by targeting Cyclin D1

Hong Liu1, Haiying Wu1, Xiangzheng Qin2

  • 1Department of Pediatrics, Daqing Longnan Hospital, Daqing City, Heilongjiang Province, China.

Pathology, Research and Practice
|August 22, 2019
PubMed

Insights

Low miR-206 levels in pediatric acute myeloid leukemia (AML) correlate with poor prognosis. Restoring miR-206 inhibits cancer cell growth, suggesting it as a potential therapeutic target for pediatric AML.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pediatric acute myeloid leukemia (AML) is a complex cancer with varied outcomes.
  • MicroRNAs (miRNAs) play a role in regulating pediatric AML progression.

Purpose of the Study:

  • To investigate the role of miR-206 in pediatric AML.
  • To assess miR-206 as a potential prognostic marker and therapeutic target.

Main Methods:

  • Measured miR-206 expression in bone marrow and serum of pediatric AML patients.
  • Conducted in vitro functional experiments on AML cells overexpressing miR-206.
  • Identified and validated miR-206 targets using molecular techniques.

Main Results:

  • miR-206 expression was significantly decreased in pediatric AML patients compared to controls.
  • Low serum miR-206 correlated with unfavorable clinicopathological features and prognosis.
  • Overexpression of miR-206 inhibited AML cell proliferation by inducing cell cycle arrest.
  • Cyclin D1 was identified as a direct target of miR-206, and its restoration rescued proliferation defects.

Conclusions:

  • miR-206 is downregulated in pediatric AML and associated with poor prognosis.
  • miR-206 functions as a tumor suppressor by inhibiting cell proliferation via targeting Cyclin D1.
  • miR-206 holds potential as a prognostic biomarker and therapeutic target for pediatric AML.
Keywords:
Cell cycleCyclin D1Pediatric acute myeloid leukemiamicroRNA-206

More Related Videos

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.6K

Related Concept Videos

Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.9K
Self-Serving Bias01:29

Self-Serving Bias

Self-serving bias is a cognitive phenomenon in which individuals attribute positive outcomes to internal factors such as their abilities, intelligence, or effort while attributing negative outcomes to external circumstances. This cognitive distortion helps maintain self-esteem but can also impede objective self-assessment.Theoretical Explanations of Self-Serving BiasTwo primary theories explain the self-serving bias: the cognitive explanation and the motivational explanation.The cognitive...
215
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214